PROCEPT BioRobotics stock (US74271T1060): Sharp decline signals market caution

PROCEPT BioRobotics fell 10.42% on May 13, 2026, closing at $25.70 as analysts weigh growth prospects against near-term headwinds in the robotic surgery device market.

PROCEPT BioRobotics (PRCT) experienced a significant single-day decline of 10.42% on Wednesday, May 13, 2026, dropping from $28.69 to $25.70, according to StockInvest as of May 13, 2026. The move reflects broader market sentiment around the medical robotics company as investors reassess valuation and near-term execution risks.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: PROCEPT BioRobotics Corporation
• Sector/industry: Medical devices, robotic surgery systems
• Headquarters/country: United States
• Core markets: Urology, robotic-assisted surgical systems
• Key revenue drivers: System placements, procedure volumes, international expansion
• Home exchange/listing venue: Nasdaq (PRCT)
• Trading currency: USD

PROCEPT BioRobotics: core business model

PROCEPT BioRobotics develops and commercializes robotic-assisted surgical systems focused on urological procedures. The company's primary product, the Aquabeam Robotic System, uses waterjet technology to perform minimally invasive treatments. The business model centers on recurring revenue from system placements at hospitals and surgical centers, combined with ongoing procedure-related consumables and service contracts. This recurring revenue structure is typical in the medical device sector and provides visibility into future cash flows.

Main revenue and product drivers for PROCEPT BioRobotics

System placements and procedure volume growth represent the primary revenue engines. According to analyst commentary cited in TipRanks as of May 2026, third-quarter metrics suggest room for upside, with sequential procedure growth and international expansion cited as key opportunities. Management guidance on 2026 performance is expected to be critical for investor confidence. The company operates in a competitive landscape that includes iRhythm Technologies, Bausch + Lomb, and other medical device manufacturers, according to MarketBeat as of May 2026.

Analyst perspective and valuation

Despite the recent price decline, analyst consensus remains constructive on longer-term prospects. The consensus price target stands at $67.50, implying potential upside of approximately 163% from the May 13 close, according to MarketBeat data. One analyst maintains an Outperform rating, citing 30%-plus sales growth expectations and a valuation of 4 times 2026 sales as supportive of share appreciation. However, the recent sell-off suggests some investors are taking profits or reassessing near-term execution risks, particularly around system placement targets and international growth rates.

Conclusion

PROCEPT BioRobotics faces a near-term valuation reset following the 10.42% single-day decline on May 13, 2026. While analyst consensus remains constructive on long-term growth driven by procedure volume expansion and international penetration, the recent sell-off reflects investor caution around near-term execution and system placement targets. US investors tracking the medical device sector should monitor upcoming quarterly results and management guidance for clarity on 2026 performance and the sustainability of the company's growth narrative.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.